eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Evaluating the Use of Backup Solutions for ePRO Systems” has been publ
October 25, 2022-October 27, 2022 2022 C-Path Neuroscience Annual Meeting C-Path’s Neuroscience Program (CPAD, CPP, CP-RND, CPTA, D-RSC, HD-RSC) is pleased to host the 2022 C-Path Neuroscience Annua
October 29, 2022 View Now | The Role of Integrated Datasets in Addressing Rare Diseases Research Challenges Gaining knowledge on rare diseases is limited by the scarcity and dispersity of patient data. Sequencing technologies have greatly
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation Board names Dr. Daniel Jorgensen as Chief Executive Officer TUCSON, Ariz., Sept. 27, 2022 — Critical Path Institute (C-Path) tod
September 21, 2022 Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports
C-Path’s European Nonprofit Appoints Managing Director and New Board Member to Expand Global Efforts TUCSON, Ariz. and AMSTERDAM, September 20, 2022 — Critical Path Institute’s (C-Path) European nonprofit today announced the ap
Rare Disease Workshop Highlights the Importance of Data Sharing in Drug Development C-Path, NORD and FDA hosted an annual workshop September 13-14 to spotlight the impact of their innovative data and analytics plat
C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases TUCSON, Ariz., Sept. 14, 2022 — Critical Path Institute (C-Path) has announced it will serve as the convener of the Critical Pat
C-Path’s Kristen Swingle Named President Swingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-
September 7, 2022 Evaluating the Use of Backup Solutions for ePRO Systems has been published in Applied Clinical Trials